Eli Lilly and Co. has entered an agreement with Hydra Biosciences to acquire all assets related to Hydra’s preclinical program of TRPA1 antagonists, part of the Transient Receptor Potential (TRP) family of ion channels being studied for the potential treatment of chronic pain syndromes. “At Lilly, we are committed to developing new treatment options for people struggling with chronic pain,” said Mark Mintun, M.D., vice president of pain and neurodegeneration research at Lill...